Insider Selling: DexCom (NASDAQ:DXCM) Director Sells $60,730.12 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 6.6%

Shares of NASDAQ DXCM opened at $61.63 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a market cap of $23.78 billion, a P/E ratio of 26.34, a P/E/G ratio of 1.06 and a beta of 1.40. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The stock has a fifty day moving average price of $63.46 and a 200 day moving average price of $65.89.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the firm earned $0.32 EPS. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent research reports. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Canaccord Genuity Group set a $100.00 price target on DexCom and gave the company a “buy” rating in a report on Friday, May 1st. Sanford C. Bernstein set a $77.00 price target on DexCom in a report on Friday, May 1st. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Finally, TD Cowen lowered their price target on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $83.22.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Trust Co. of Vermont boosted its position in DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares during the last quarter. CVA Family Office LLC boosted its position in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the last quarter. V Square Quantitative Management LLC boosted its position in DexCom by 1.8% in the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares during the last quarter. Essex Financial Services Inc. boosted its position in DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after buying an additional 178 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.